Free tool
FAERS Monitor: Granix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125294 or its brand name (Granix, Tbo-Filgrastim). Reports on generic versions are filed under their own applications.
Reports
871
Serious
542
62% of reports
Hospitalization
274
Death reported
129
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death79
- fatigue70
- white blood cell count decreased53
- diarrhoea44
- drug ineffective40
- nausea40
- neutropenia40
- off label use40
- pyrexia32
- asthenia30
- febrile neutropenia29
- pneumonia28
- cytokine release syndrome27
- thrombocytopenia24
- headache23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 23 |
| 2015 | 46 |
| 2016 | 58 |
| 2017 | 62 |
| 2018 | 113 |
| 2019 | 115 |
| 2020 | 120 |
| 2021 | 130 |
| 2022 | 61 |
| 2023 | 54 |
| 2024 | 37 |
| 2025 | 25 |
| 2026 | 27 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,288 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytokine release syndromeSignal | 27 | 32.5 | 22.4 | 794 |
| white blood cell count decreasedSignal | 53 | 11.8 | 9.1 | 516 |
| febrile neutropeniaSignal | 29 | 10.6 | 7.4 | 242 |
| neutropeniaSignal | 40 | 7.1 | 5.2 | 205 |
| thrombocytopeniaSignal | 24 | 5.2 | 3.5 | 77 |
| pyrexiaSignal | 32 | 2.2 | 1.6 | 21 |
| deathSignal | 79 | 2.2 | 1.8 | 54 |
| fatigueSignal | 70 | 2.2 | 1.7 | 45 |
| pneumoniaSignal | 28 | 2.1 | 1.5 | 15 |
| asthenia | 30 | 1.9 | 1.4 | 13 |
| diarrhoea | 44 | 1.6 | 1.2 | 11 |
| nausea | 40 | 1.2 | 0.9 | 1 |
| off label use | 40 | 1.1 | 0.8 | 0 |
| headache | 23 | 0.9 | 0.6 | 0 |
| drug ineffective | 40 | 0.7 | 0.5 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.